Monoeffect or combinative effect and their mechanism of HSF1 and P53 on the sensitivity of pancreatic cancer treated by 125I radiotherapy

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800017794

Enrollment

Unknown

Registered

2018-08-15

Start date

2018-09-01

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Group 1:125I

Group 2:125I+P53

Group 3:125I+tripterygium glycosides

Group 4:P53

Group 5:tripterygium glycosides

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: late pancreatic cancer patients

Exclusion criteria

Exclusion criteria: pancreatitis patients

Design outcomes

Primary

Measure	Time frame
survival time;	—

Secondary

Measure	Time frame
size of tumour;pain score;BLOOD VEGF;	—

Countries

China

Contacts

Public Contactguiliang wang

Pingxiang People's Hospital, Jiangxi

guiliangwang@126.com+86 079 96881797

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026